glp-1 microdosing perimenopause THE PCCA BLOG Exploring Microdosing GLP-1 Medications: Benefits
Description
When switching between GLP1RAs, transient GI AEs are expected and can be reduced by slow uptitration, including use of intermediary doses, and advising patients to reduce portion sizes and fat intake
The FDA has warned about potential risks, including serious side effects, from unapproved compounded versions, especially when they use different forms of the active ingredient (like "semaglutide sodium" or "tirzepatide acetate") than the approved drugs
El K, Campbell JE
Since saliva is always present in your mouth, anything unusual in the saliva is going to be noticeable on the tongue
Symptoms include persistent abdominal pain, nausea, and vomiting
Thyroid Tumors : Animal studies have shown an increased risk of thyroid tumors, although the relevance to humans is still unclear
